Curative Biotechnology Management
Management criteria checks 3/4
Curative Biotechnology's CEO is I. Garr, appointed in Feb 2021, has a tenure of 3.58 years. directly owns 14.14% of the company’s shares, worth $1.79M. The average tenure of the management team and the board of directors is 3.6 years and 2.7 years respectively.
Key information
I. Garr
Chief executive officer
US$438.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.6yrs |
| CEO ownership | 14.1% |
| Management average tenure | 3.6yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$438k | n/a | -US$6m |
| Dec 31 2022 | US$517k | US$158k | -US$5m |
| Sep 30 2022 | n/a | n/a | -US$6m |
| Jun 30 2022 | n/a | n/a | -US$6m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$3m | US$170k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$22m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$980k | n/a | -US$5m |
Compensation vs Market: I.'s total compensation ($USD438.00K) is below average for companies of similar size in the US market ($USD677.23K).
Compensation vs Earnings: I.'s compensation has been consistent with company performance over the past year.
CEO
I. Garr (71 yo)
3.6yrs
Tenure
US$438,000
Compensation
Mr. I. Richard Garr, JD, Esq., serves as CEO, CFO, General Counsel at Connectyx Technologies Holdings Group, Inc. (formerly known as Curative Biotechnology, Inc.) since February 2021 and its Principal Acco...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Executive Chairman | 4.5yrs | US$783.11k | 7.07% $ 894.3k | |
| CEO, CFO | 3.6yrs | US$438.00k | 14.14% $ 1.8m | |
| Vice President of Communications | no data | no data | no data | |
| Executive VP of Process Product Drug Development and Member of Scientific & Clinical Advisory Board | 3.6yrs | no data | no data |
3.6yrs
Average Tenure
Experienced Management: CUBT's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Executive Chairman | 4.5yrs | US$783.11k | 7.07% $ 894.3k | |
| Executive VP of Process Product Drug Development and Member of Scientific & Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 2.3yrs | no data | no data | |
| Independent Director | 2.3yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 3.4yrs | no data | no data | |
| Chairman of the Scientific Advisory Board | 3.6yrs | no data | no data | |
| Member of Scientific & Clinical Advisory Board | 3yrs | no data | no data | |
| Independent Director | 1.4yrs | no data | no data |
2.7yrs
Average Tenure
61yo
Average Age
Experienced Board: CUBT's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.